ClinicalTrials.gg
Enrolling by invitationNCT07281729Updated Dec 15, 2025

Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders

An observational study in Bipolar Disorder;Major Depressive Disorder;Mood Disorders, sponsored by Shanghai Mental Health Center. Enrolling by invitation at 2 sites in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Shanghai Mental Health Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Ages
16 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Bipolar Disorder by Shanghai Mental Health Center — 7 open to participants now, 7 under way, none of them phase 3. Bipolar Disorder · Shanghai Mental Health Center.

Started
2025
the only one that year
Observational
8 of 16
4 open now
Registered
15th of 16
by date

Among the 16 studies in Bipolar Disorder by Shanghai Mental Health Center, this one is the only one that started in 2025, is one of 8 observational ones, and was the 15th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

7 of the 16 studies in Bipolar Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 16 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Bipolar Disorder by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Main research objective: Through questionnaire surveys, obtain the occurrence levels of self-harm/suicide behaviors, the status of acquired suicidal ability, and their correlations with self-harm/suicide behaviors among patients with mood disorders in mental specialty hospitals and general hospitals.

Main research purpose: (1) Conduct a comprehensive assessment and analysis of the occurrence of suicide/self-harm behaviors, the level of acquired suicidal ability, and their distribution among patients with mood disorders in China; (2) Compare the characteristics and acquired suicidal ability status of patients with mood disorders in mental specialty hospitals and general hospitals' psychological outpatient departments regarding suicide/self-harm behaviors; (3) From multiple dimensions, explore the influencing factors of self-harm/suicide behaviors and acquired suicidal ability in patients with mood disorders, form a list of suicide risk factors and clarify the key risk factors, establish a predictive model for acquired suicidal ability; (4) Through follow-up on whether patients have another occurrence of suicide behavior, clarify the impact of key risk factors on the occurrence of suicide behavior, and verify the effectiveness of the predictive model for acquired suicidal ability.

03

Conditions studied

  • Bipolar Disorder;Major Depressive Disorder;Mood Disorders
04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Including people with mood disorders of different ages, genders, occupations, educational levels and cultural backgrounds

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 16 and 60 years;Presenting at psychiatric hospital or psychological department of general hospital;Willing to cooperate and participate in this study; is signed (with additional informed consent provided by guardian for adolescents);Meeting the diagnostic criteria for Mood Disorders as defined by ICD-11.

Exclusion criteria

Exclusion Criteria:

  • Inable to comprehend the questionnaire content;Severe organic diseases (e.g., cardiovascular, cerebrovascular, hepatic, or renal impairments) and physically debilitated conditions influencing questionnaire completion;Other situations where participants are unable or unwilling to complete the questionnaire.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Suicidal behavior/suicide death questionnaire

    The one-year follow-up work for 1000 patients (including the main center and 9 representative sub-centers) was completed. Suicidal behavior/suicide death was used as the primary outcome indicator. The follow-up was conducted once every 3 months (via offline interviews; if the patient was unable to come in person, telephone visits were considered), and the content included whether suicidal/self-harming behavior occurred, the current status, and the baseline part of the questionnaire, etc.

    Time frame: 1 year

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — The prescription data will not be shared with the public. However, if the intervention is effective, the educational materials will be released to the public

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

Of 95 non-industry observational studies under Bipolar Disorder, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's planned 10 months is below that.

Counting every sponsor, half of 105 studies reached it within 64 months; a quarter within 31 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 15, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07281729
Responsible party
PENG, Daihui (Chief Physician, Shanghai Mental Health Center) — Principal investigator
First posted
Dec 15, 2025
Start date
Aug 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion